首页> 美国卫生研究院文献>Journal of Lipid Research >Lipoprotein metabolism in familial hypercholesterolemia
【2h】

Lipoprotein metabolism in familial hypercholesterolemia

机译:脂蛋白代谢在家族性高胆固醇血症

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Familial hypercholesterolemia (FH) is one of the most common genetic disorders in humans. It is an extremely atherogenic metabolic disorder characterized by lifelong elevations of circulating LDL-C levels often leading to premature cardiovascular events. In this review, we discuss the clinical phenotypes of heterozygous and homozygous FH, the genetic variants in four genes (LDLR/APOB/PCSK9/LDLRAP1) underpinning the FH phenotype as well as the most recent in vitro experimental approaches used to investigate molecular defects affecting the LDL receptor pathway. In addition, we review perturbations in the metabolism of lipoproteins other than LDL in FH, with a major focus on lipoprotein (a). Finally, we discuss the mode of action and efficacy of many of the currently approved hypocholesterolemic agents used to treat patients with FH, with a special emphasis on the treatment of phenotypically more severe forms of FH.
机译:家族性高胆固醇血症(FH)是人类中最常见的遗传疾病之一。它是一种极其致动的代谢障碍,其特征在于循环LDL-C水平的终身升高,通常导致过早心血管事件。在本综述中,我们讨论了杂合和纯合的FH,四种基因的遗传变异(LDLR / APOB / PCSK9 / LDLRAP1)的临床表型(LDLR / APOB / PCSK9 / LDLRAP1),其基于FH表型以及用于研究影响分子缺陷的最新体外实验方法LDL受体途径。此外,我们在FH中的LDL以外的LDL以外的脂蛋白代谢中审查扰动,主要侧重于脂蛋白(A)。最后,我们讨论了许多目前批准的次粒化药物的作用和疗效模式,用于治疗FH的患者,特别强调治疗表型更严重的FH。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号